Join our daily newsletter At The Bell to receive exclusive market insights
- Global biopharmaceutical Bionomics has submitted an application to Fast Track a drug to treat Post Traumatic Stress Disorder (PTSD)
- BNC210 is described as Bionomic’s lead drug candidate. It’s been tested during clinical trials on the elderly, as well as people suffering from PTSD and generalised anxiety disorders
- If successful, fast tracking the drug (currently under clinical appraisal and known as BNC210) will speed up the trial process and cut down the time needed to bring the remedy to the market
Global biopharmaceutical Bionomics has submitted an application to fast track a drug to treat Post Traumatic Stress Disorder (PTSD).
If successful, fast tracking the drug (currently under clinical appraisal and known as BNC210) will speed up the trial process and cut down the time needed to bring the remedy to the market.
The announcement comes after the company entered discussions about BNC210’s trial with the Food and Drug Administration in the U.S., seeking guidance about the remedy’s future post-trial.
Earlier reports from Bionomics indicate the FDA is on board with the drug’s current trajectory and is supportive of the application to fast track BNC210’s development.
Most of the company’s existing drug candidates are also in the early to mid-stages of pharmaceutical development, currently undergoing clinical trials.
BNC210 is described as Bionomics’ lead drug prospect. It’s been tested during clinical trials on the elderly, as well as people suffering from PTSD and generalised anxiety disorders.
Currently, BNC210 is administered orally, but outstanding trials could allow for the development of a solid formulation. Results from the incumbent tabulation trial should be released next month.
Bionomics executive chairman Dr Errol De Souza said the analysis would provide the groundwork for future trials demonstrating the drug’s efficacy.
“Our exposure-response modelling has shown the potential for BNC210 to have significant benefit in PTSD provided adequate blood levels are achieved,” Dr Errol said.
“There is great unmet medical need for safe and effective treatments for the large population of patients suffering with PTSD worldwide,” he concluded.
Bionomics, a clinical biopharmaceutical company, specialises in developing treatments for central nervous system disorders like anxiety, depression and Alzheimer’s disease.
Stocks in the company were up 33.33 per cent this morning, currently trading at 5.2 cents apiece. Bionomics’ market cap is valued at A$21.24 million.
